Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).

Riedel R, Verheyen M, Michels S, Ruge L, Stilianakis S, Jakob C, Scharpenseel H, Scheffler M, Nogova L, Schulmann K, Bozorgmehr F, Grohe C, Griesinger F, Welter V, Fassunke J, Siemanowski-Hrach J, Tolkach Y, Siebolts U, Merkelbach-Bruse S, Büttner R, Wolf J, John F

Open source

DOI: 10.1016/j.cllc.2026.08.001
Published: 2026 Aug 11
Container: Clinical lung cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.08.001,
  title = {Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).},
  author = {Riedel R and Verheyen M and Michels S and Ruge L and Stilianakis S and Jakob C and Scharpenseel H and Scheffler M and Nogova L and Schulmann K and Bozorgmehr F and Grohe C and Griesinger F and Welter V and Fassunke J and Siemanowski-Hrach J and Tolkach Y and Siebolts U and Merkelbach-Bruse S and Büttner R and Wolf J and John F},
  year = {2026},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2026.08.001},
  url = {https://doi.org/10.1016/j.cllc.2026.08.001}
}

RIS

TY  - JOUR
TI  - Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).
AU  - Riedel R
AU  - Verheyen M
AU  - Michels S
AU  - Ruge L
AU  - Stilianakis S
AU  - Jakob C
AU  - Scharpenseel H
AU  - Scheffler M
AU  - Nogova L
AU  - Schulmann K
AU  - Bozorgmehr F
AU  - Grohe C
AU  - Griesinger F
AU  - Welter V
AU  - Fassunke J
AU  - Siemanowski-Hrach J
AU  - Tolkach Y
AU  - Siebolts U
AU  - Merkelbach-Bruse S
AU  - Büttner R
AU  - Wolf J
AU  - John F
PY  - 2026
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2026.08.001
UR  - https://doi.org/10.1016/j.cllc.2026.08.001
ER  -

APA

R, R., M, V., S, M., L, R., S, S., C, J., H, S., M, S., L, N., K, S., F, B., C, G., F, G., V, W., J, F., J, S., Y, T., U, S., S, M., R, B., J, W., & F, J. (2026). Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.08.001

Source records

pubmed · retrieved 2026-09-25T07:01:15.405Z